Dublin, June 27, 2019 (GLOBE NEWSWIRE) -- The "V114" report has been added to ResearchAndMarkets.com's offering.
Merck & Co's V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
V114 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as two additional serotypes (22F and 33F). Merck & Co is testing both an aluminum-adjuvanted and non-adjuvanted version of the vaccine.
Research Outlook
V114's (15-valent pneumococcal conjugate vaccine; Merck & Co) broader serotype coverage gives it significant market potential, should it demonstrate broader immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase III studies.
If serotype shift occurs, V114 could replace Prevnar 13 on the market for adults aged 50 years and older due to its broader coverage and greater diversity in serotypes.
Key Topics Covered
- Drug Overview
- Product Profiles
- V114 : Pneumococcal vaccines
List of Figures
Figure 1: V114 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: V114 drug profile
Table 2: Trials of V114 for pneumococcal vaccination
Table 3: V114 for pneumococcal vaccination - SWOT analysis
For more information about this report visit https://www.researchandmarkets.com/r/pgg5h6
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.